Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused...
Cancer
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated...
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration...
Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101),...
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MIAMI, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused...
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing...
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA®,...
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved...
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly...
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”Initial data...
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the...
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Clinical Trials – Outlook And Trends For 2023
Clinical trials for testing potential drugs, procedures, or devices have evolved over hundreds of years. Scientists use clinical trials on...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated...
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination...
ORYZON to Give Updates on Corporate Progress in February-March
BIO CEO & Investor Conference 2023IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer...
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the...